theMednetRegister
Br J Haematol 2021 Jun 10
Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study.   

Related Questions

Do you have any concerns about using checkpoint inhibitors in a patient with myeloma who has a second malignancy?
Patient with stable disease on maintenance therapy with lenalidomide and dexamethasone
New answer by Medical Oncologist at Medical University of South Carolina (May 5, 2023)
In clinical trials, the development of a second malignancy (SM) has been considered as an indication to discontinue treatment. [Having seen people die from lenalidomide-relate...
For a patient with a metastatic solid tumor in remission on a checkpoint inhibitor who also has R/R multiple myeloma, would you feel comfortable with a bispecific T-cell engager antibody?
This is rare but I've seen it twice last year! One with melanoma on nivolumab and one with lung cancer on pembrolizumab (both cases in deep remission)...
New comment by Medical Oncologist at Winship Cancer Institute of Emory University ( April 8, 2025)
Comprehensive, clear, and actionable. Thanks!
Copyright © 2025 theMednet
All Rights Reserved.